natgillin/translations-raw huggingface dataset:
According to subgroup analysis in children at 1 to 12 years of age, the incidence of laboratory-confirmed clinical influenza among children was significantly reduced from 19 % (21 / 111) in the group not receiving prevention to 7 % (7 / 104) in the group receiving prevention (64.4 % reduction [95 % CI 15.8 - 85.0; p = 0.0188]).
Prema analizi podskupine djece u dobi od 1 do 12 godina došlo je do znatnog smanjenja incidencije laboratorijski potvrđene klinički izražene gripe: od 19 % (21/111) u skupini u kojoj nije provedena prevencija, na 7 % (7/104) u skupini u kojoj je prevencija provedena (smanjenje od 64,4 % [95 % CI 15,8 - 85,0; p = 0,0188]).
By day 6 (the last day of treatment) FEV1 had increased by 10.8 % in the oseltamivir treated group compared to 4.7 % on placebo (p = 0.0148) in this population.
10,8 % u skupini koja je primala oseltamivir u odnosu na 4,7 % u skupini koja je primala placebo (p = 0,0148).
Otitis media,
Infekcije i infestacije otitis media
3.0 ml (or 5.0 ml)
3,0 ml (ili 5,0 ml)
With a suitable stirring device, stir for 2 minutes.
Miješajte 2 minute prikladnim priborom.
• Mild to severe liver function disorders
• poremećaji srčanog ritma • blagi do teški poremećaji funkcije jetre
Yellow iron oxide (E172) Titanium dioxide (E171)
Ovojnica kapsule želatina željezov oksid, žuti (E172) titanijev dioksid (E171)
In households of influenza-infected index cases, there was a reduction in the incidence of influenza from 26 % (23 / 89) in the group not receiving prevention to 11 % (9 / 84) in the group receiving prevention (58.5 % reduction [95 % CI 15.6 - 79.6; p = 0.0114]).
U kućanstvima u kojima su postojali indeks slučajevi zaraženi gripom došlo je do smanjenja incidencije gripe: od 26 % (23/89) u skupini u kojoj nije provedena prevencija, na 11 % (9/84) u skupini u kojoj je prevencija provedena (smanjenje od 58,5 % [95 % CI 15,6 - 79,6; p = 0,0114]).
10 kg or more
10 kg ili više
Children (1-12 years)
Odrasli i adolescenti Djeca (1-12 godina)
This dosing recommendation is not intended for premature infants, i.e. those with a postconceptual age less than 36 weeks.
Ova preporuka za doziranje prema dobi nije namijenjena za nedonoščad, to jest dojenčad s manje od
Step 1: Pour all the powder into a bowl
1. korak: Istresite sav prah u zdjelicu
[Only applicable for outer packaging:] Ebilfumin 30 mg
[Primjenjivo samo za vanjsko pakiranje:] Ebilfumin 30 mg
> 7 kg to 10 kg
> 7 kg do 10 kg
Metabolite exposures are also more variable in the youngest infants.
U najmlađe je dojenčadi varijabilnija i izloženost metabolitu.
5.0 ml (or 10.0 ml)
5,0 ml (ili 10,0 ml)
Treatment: The recommended treatment dose for infants 0 - 12 months of age is 3 mg/kg twice daily.
Liječenje: Tijekom izbijanja pandemije gripe preporučena terapijska doza za dojenčad u dobi od 012 mjeseci iznosi 3 mg/kg dvaput dnevno.
You should use only 45 mg capsules for 45 mg doses.
Za dozu od 45 mg smijete koristiti samo kapsule od 45 mg.
[Only applicable for outer packaging:] Ebilfumin 45 mg
[Primjenjivo samo za vanjsko pakiranje:] Ebilfumin 45 mg
The proportion of subjects who developed specified lower respiratory tract complications (mainly bronchitis) treated with antibiotics was reduced from 12.7 % (135/1,063) in the placebo group to 8.6 % (116/1,350) in the oseltamivir treated population (p = 0.0012).
Udio ispitanika u kojih su se razvile specifične komplikacije donjih dišnih putova (uglavnom bronhitis) koje su se morale liječiti antibioticima, smanjio se s 12,7 % (135/1063) u skupini koja je primala placebo, na 8,6 % (116/1350) u skupini koja se liječila oseltamivirom (p = 0,0012).
30 mg single dose * Data derived from studies in continuous ambulatory peritoneal dialysis (CAPD) patients; the clearance of oseltamivir carboxylate is expected to be higher when automated peritoneal dialysis (APD) mode is used.
* Podaci dobiveni u ispitivanjima bolesnika na kontinuiranoj ambulantnoj peritonejskoj dijalizi (CAPD); očekuje se da će klirens oseltamivir karboksilata biti veći ako se primjenjuje automatizirana peritonejska dijaliza (APD).
Storage of the pharmacy compounded suspension Shelf life of 3 weeks when stored below 25 °C.
Rok valjanosti je 3 tjedna ako se čuva na temperaturi ispod 25°C.
When commercially manufactured oseltamivir powder for oral suspension is not available, a pharmacy compounded suspension prepared from Ebilfumin capsules must be used (see detailed instructions above).
Priprema kod kuće Kada tvornički proizveden oseltamivir prašak za oralnu suspenziju nije dostupan, mora se koristiti ljekarnički pripravak suspenzije iz Ebilfumin kapsula (vidjeti podrobne upute u prethodnom tekstu).
There are no data available for infants below 1 year of age for post exposure prevention of influenza.
Nema dostupnih podataka o prevenciji gripe nakon izlaganja virusu u dojenčadi mlađe od 1 godine.
You will need to prepare a dose of less than 75 mg for children who weigh less than 40 kg. See below.
Za djecu čija je tjelesna težina manja od 40 kg morat ćete pripremiti dozu manju od 75 mg.
• Upset stomach.
• bol u trbuhu
Infants less than 1 year (including full-term newborn babies) Child's weight
Djeca mlađa od 1 godine (uključujući novorođenčad rođenu na vrijeme)
Oral dose dispensers (oral syringes) of appropriate volume and grading should be provided for administering the pharmacy compounded suspension, and for the procedures involved in the home preparation.
Moraju se osigurati štrcaljke za usta (oralne štrcaljke) odgovarajućeg volumena i s odgovarajućim mjernim oznakama za potrebe davanja suspenzije pripremljene u ljekarni i za potrebe pripreme kod kuće.
At 500 mg/kg, no adverse reactions were seen, including upon chronic treatment (500 mg/kg/day administered from 7 to 21 days post partum).
(500 mg/kg/dan primijenjeno od 7. do 21. dana nakon poroda).
The appropriate dose must be mixed by the caregiver with an equal quantity of sweet liquid food, such as sugar water, chocolate syrup, cherry syrup, dessert toppings (like caramel or fudge sauce) to mask the bitter taste.
Kako bi se prikrio gorak okus lijeka, neposredno prije davanja njegovatelj mora izmiješati propisanu dozu lijeka s jednakom količinom slatke tekuće hrane, poput zašećerene vode, čokoladnog sirupa, sirupa okusa trešnje, desertnog preljeva (poput preljeva od karamela ili čokolade).
Cardiac arrhythmia
Srčani poremećaji srčana aritmija
Shellac Glaze-45% (20% esterified) Black iron oxide (E172) Propylene glycol (E1520) Ammonium hydroxide 28% (E527)
Tinta za označivanje šelak glazura-45% (20% esterificirana) željezov oksid, crni (E172) propilenglikol (E1520) amonijev hidroksid 28% (E527)
• If you have the right capsule for the dose needed (a 30 mg or a 60 mg dose), you will open the capsule and stir its contents into one teaspoon (or less) of a suitable sweetened food product.
• Ako imate odgovarajuću kapsulu za dozu koja je potrebna (dozu od 30 mg ili 60 mg), otvorit ćete kapsulu i njezin sadržaj umiješati u jednu čajnu žličicu (ili manje) prikladne slatke hrane.
Step 2: Pour all the powder into a bowl
2. korak: Istresite sav prah u zdjelicu
Dosing chart for pharmacy-compounded 6 mg/ml suspension prepared from Ebilfumin capsules for infants and children 1 year of age or older Body weight (kg)
Tablica doziranja za suspenziju koncentracije 6 mg/ml pripremljenu iz Ebilfumin kapsula u ljekarni, za dojenčad i djeci u dobi od 1 godine i stariju
The hard capsule consists of a white opaque body and a rich yellow cap bearing the black imprint “OS 75”.
Tvrda kapsula se sastoji bijelog neprozirnog tijela i intenzivno žute kapice s crnim natpisom „OS 75“.
• Upper abdominal fullness • Upset stomach.
• osjećaj punoće u gornjem dijelu trbuha • želučane tegobe
In the pooled treatment study population, which included both influenza-positive and -negative subjects (ITT), primary efficacy was reduced proportionally to the number of influenza-negative individuals.
intention to treat), primarna se djelotvornost smanjivala razmjerno broju influenca-negativnih ispitanika.
vertigo), Fatigue, Pyrexia , Pain in limb
(uključujući vrtoglavicu), umor, pireksija, bol u udovima
There was no resistance observed during a 12-week prophylaxis study in immunocompromised patients.
Kod imunokompromitiranih bolesnika nije opažena rezistencija na lijek tijekom ispitivanja profilakse u trajanju od 12 tjedana.
> 10 to 30 (ml/min)
> 10 do 30 (ml/min)
Clinical studies: The risk of emergence of influenza viruses with reduced susceptibility or frank resistance to oseltamivir has been examined during Roche-sponsored clinical studies.
Klinička ispitivanja: Tijekom Roche sponzoriranih kliničkih ispitivanja provedena su ispitivanja rizika pojave virusa gripe smanjene osjetljivosti ili rezistentnih na oseltamivir.
> 30 to 60 (ml/min)
> 30 do 60 (ml/min)
• Upset stomach
• poremećaj bubnjića
75 mg once daily
75 mg jednom dnevno
In influenza-positive patients with chronic cardiac and/or respiratory disease, the combined incidence of lower respiratory tract complications (mainly bronchitis) treated with antibiotics was 17 % (22/133) in the placebo group and 14 % (16/118) in the oseltamivir treated population (p = 0.5976).
U influenca-pozitivnih bolesnika s kroničnim srčanim i/ili respiratornim bolestima, incidencija komplikacija donjih dišnih putova (uglavnom bronhitisa) liječenih antibioticima bila je 17 % (22/133)
20 capsules (600 mg)
20 kapsula (600 mg)
Nervous system disorders
Psihijatrijski poremećaji i poremećaji živčanog sustava
> 23 kg to 40 kg
> 23 kg do 40 kg
Examples are: chocolate or cherry syrup and dessert toppings such as caramel or fudge sauce.
To može biti čokoladni sirup, sirup s okusom trešnje ili desertni preljevi, primjerice preljev od karamela ili čokolade.
Актавис ЕАД Teл.
Actavis Ltd.
Among children who were not already shedding virus at baseline, the incidence of laboratory-confirmed clinical influenza was reduced from 21 % (15 / 70) in the group not receiving prevention to 4 % (2 / 47) in the group receiving prevention (80.1 % reduction [95 % CI 22.0 - 94.9; p = 0.0206]).
Među djecom koja na početku nisu bila nositelji virusa došlo je do smanjenja incidencije laboratorijski potvrđene klinički izražene gripe: od 21 % (15/70) u skupini u kojoj nije provedena prevencija, na 4 % (2/47) u skupini u kojoj je prevencija provedena (smanjenje od 80,1 % [95 % CI 22,0 - 94,9; p = 0,0206]).
The hard capsule consists of a rich yellow body and cap bearing the black imprint “OS 30”.
Tvrda kapsula se sastoji od intenzivno žutog tijela i kapice s crnim natpisom „OS 30“.
3.0 ml twice daily 3.0 ml once daily 3.0 ml (or 5.0 ml)
3,0 ml dvaput dnevno 3,0 ml jednom dnevno 3,0 ml (ili 5,0 ml)
Haemodialysis patients
bolesnici na hemodijalizi
> 15 kg to 23 kg
> 15 kg do 23 kg
40 kg or more
40 kg ili više
Prevention during an influenza epidemic in the community: Prevention during an influenza epidemic has not been studied in children 0-12 months of age.
Prevencija tijekom epidemije gripe u zajednici: Prevencija tijekom epidemije gripe nije ispitivana u djece u dobi od 0 - 12 mjeseci.
Look at the right column to check the number of capsules you will need to give the patient for a single dose.
Pogledajte stupac na desnoj strani tablice da provjerite koliko kapsula
12 capsules (360 mg)
12 kapsula (360 mg)
Treating flu:
Liječenje gripe:
18 capsules (540 mg)
18 kapsula (540 mg)
23 to 40 kg
23 do 40 kg
oseltamivir significantly reduced the incidence of specified lower respiratory tract complications (mainly bronchitis) treated with antibiotics from 19 % (52/268) in the placebo group to 12 % (29/250) in the oseltamivir treated population (p = 0.0156).
U starijih influenca-pozitivnih osoba oseltamivir je značajno smanjio incidenciju specifičnih komplikacija donjih dišnih putova (uglavnom bronhitisa), koje su se liječile antibioticima s 19 % (52/268) u skupini koja je primala placebo, na 12 % (29/250) u skupini koja je primala oseltamivir (p = 0,0156).
Adults, and adolescents 13 years and over
Odrasli i adolescenti u dobi od 13 godina i stariji
Data from 504 influenza B infected subjects were pooled across all studies for analysis.
Iz svih su provedenih ispitivanja radi analize prikupljeni i objedinjeni podaci o 504 bolesnika zaražena virusom gripe tipa B.
Ebilfumin 75 mg hard capsules are available in blister packs or tablet containers of 10.
Ebilfumin 75 mg tvrde kapsule su dostupne u blister pakiranjima ili spremnicima s tabletama od 10 kapsula.
(may affect up to 1 in 1,000 people)
(mogu se javiti u najviše 1 na 1000 osoba)
Prevention during an influenza epidemic in the community: Prevention during an influenza epidemic has not been studied in children below 12 years of age.
Prevencija tijekom epidemije gripe u zajednici: Prevencija tijekom epidemije gripe nije ispitivana u djece mlađe od 12 godina.
The hard capsule consists of a white opaque body and cap bearing the black imprint “OS 45”.
Tvrda kapsula se sastoji od bijelog neprozirnog tijela i kapice s crnim natpisom „OS 45“.
Ebilfumin 75 mg hard capsules
Ebilfumin 75 mg tvrde kapsule
Ebilfumin 30 mg hard capsules are available in blister packs or tablet containers of 10.
Ebilfumin 30 mg tvrde kapsule su dostupne u blister pakiranjima ili spremnicima s tabletama od 10 kapsula.
The NNT in this study was 28 (95 % CI 24 - 50).
Broj osoba koje je bilo potrebno liječiti da bi se spriječio jedan slučaj gripe (NNT) u tom je ispitivanju bio 28 (95 % CI 24 - 50).
Fulminant hepatitis, Hepatic failure, Hepatitis
Poremećaji jetre i žuči povišine razine jetrenih enzima fulminantni hepatitis, zatajenje jetre, hepatitis
25 capsules (750 mg)
25 kapsula (750 mg)
60 mg once daily
60 mg jednom dnevno
8 capsules (360 mg)
8 kapsula (360 mg)
There has been no evidence for emergence of drug resistance associated with the use of oseltamivir in clinical studies conducted to date in post-exposure (7 days), post-exposure within household groups (10 days) and seasonal (42 days) prevention of influenza in immunocompetent patients.
U dosad provedenim kliničkim ispitivanjima prevencije gripe nakon prethodne izloženosti virusu (7 dana), nakon prethodne izloženosti virusu u kućanstvima (10 dana) i u sezoni gripe (42 dana), kod osoba s normalnim imunim odgovorom nije bilo dokaza pojave rezistencije na lijek povezane s upotrebom oseltamivira.
30 mg once daily
30 mg jednom dnevno
Ebilfumin 30 mg hard capsules
Ebilfumin 30 mg tvrde kapsule
Ebilfumin 45 mg hard capsules are available in blister packs or tablet containers of 10.
Ebilfumin 45 mg tvrde kapsule su dostupne u blister pakiranjima ili spremnicima s tabletama od 10 kapsula.
1.8 ml twice daily 1.8 ml once daily 2.0 ml (or 3.0 ml)
1,8 ml dvaput dnevno 1,8 ml jednom dnevno 2,0 ml (ili 3,0 ml)
In lactating rats, oseltamivir and the active metabolite are excreted in the milk.
U ženki štakora se u laktacijskom razdoblju oseltamivir i njegov aktivni metabolit izlučuju u mlijeko.
Treatment: The following weight-adjusted dosing regimens are recommended for treatment of infants and children 1 year of age or older:
Liječenje: Za dojenčad i djecu u dobi od 1 godine i stariju su preporučena sljedeća doziranja prilagođena tjelesnoj težini:
Visual disturbance
Poremećaji oka smetnje vida
10 kg to 15 kg
10 kg do 15 kg
Infants less than 1 year To make a smaller single dose, you need:
Da biste pripremili jednu manju dozu, potrebno Vam je:
Treatment: The recommended oral dose is 75 mg oseltamivir twice daily for 5 days for adolescents (13 to 17 years of age) and adults.
Liječenje: Preporučena peroralna doza oseltamivira za adolescente (u dobi od 13 do 17 godina) i odrasle iznosi 75 mg dvaput dnevno tijekom 5 dana.
(may affect up to 1 in 100 people)
(mogu se javiti u najviše 1 na 100 osoba)
- The appropriate use of Ebilfumin for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection.
- Prikladnost upotrebe lijeka Ebilfumin za prevenciju gripe određuje se za svaki slučaj zasebno,
• If you have the right capsule strength for the dose needed (a 75 mg dose), you will open the capsule and stir its contents into one teaspoon (or less) of a suitable sweetened food product.
• Ako imate odgovarajuću jačinu kapsule za dozu koja je potrebna (dozu od 75 mg), otvorit ćete kapsulu i njezin sadržaj umiješati u jednu čajnu žličicu (ili manje) prikladne slatke hrane.
• If you have the right capsule for the dose needed (a 45 mg dose), you will open the capsule and stir its contents into one teaspoon (or less) of a suitable sweetened food product.
• Ako imate odgovarajuću kapsulu za dozu koja je potrebna (dozu od 45 mg), otvorit ćete kapsulu i njezin sadržaj umiješati u jednu čajnu žličicu (ili manje) prikladne slatke hrane.
30 mg after every second haemodialysis session
30 mg nakon svake druge hemodijalize bolesnici na peritonejskoj dijalizi*
8 capsules (600 mg)
8 kapsula (600 mg)
Commercially manufactured oseltamivir powder for oral suspension (6 mg/ml) is the preferred product for paediatric and adult patients who have difficulties swallowing capsules or where lower doses are needed.
Komercijalno proizvedeni prašak oseltamivira za oralnu suspenziju (6 mg/ml) je proizvod kojem se daje prednost kod pedijatrijskih i odraslih bolesnika koji imaju poteškoća s gutanjem kapsula, ili ako su potrebne manje doze lijeka.
10 to 15 kg
10 do 15 kg
• One or two 30 mg Ebilfumin capsule(s)
• jedna ili dvije Ebilfumin kapsule od 30 mg
3 kg to 10+ kg
3 kg do 10 + kg
Altered level of consciousness, Convulsion
Poremećaji živčanog sustava glavobolja nesanica promijenjena razina svijesti, konvulzije
The NNT in this study was 25 (95 % CI 23 - 62).
Broj osoba koje je bilo potrebno liječiti da bi se spriječio jedan slučaj gripe (NNT) u tom je ispitivanju bio 25 (95 % CI 23 - 62).
Treatment of influenza in children: In a study of otherwise healthy children (65 % influenza-positive) aged 1 to 12 years (mean age 5.3 years) who had fever (≥ 37.8 °C) plus either cough or coryza, 67 % of influenza-positive patients were infected with influenza A and 33 % with influenza B. Oseltamivir treatment, started within 48 hours of onset of symptoms, significantly reduced the time to freedom from illness (defined as the simultaneous return to normal health and activity and alleviation of fever, cough and coryza) by 1.5 days (95 % CI 0.6 - 2.2 days; p < 0.0001) compared to placebo.
33 % gripom B. Liječenje oseltamivirom, započeto u roku od 48 sati po izbijanju simptoma, značajno je smanjilo vrijeme do ozdravljenja (definirano kao istovremeni povratak normalnoga zdravlja i aktivnosti te ublažavanje temperature, kašlja i hunjavice) za 1,5 dan (95 % CI 0,6 - 2,2 dana, p<0,0001) u odnosu na placebo.
Up to 15 kg
Do 15 kg
The study included solid organ transplant [SOT] patients, haematopoietic stem cell transplant [HSCT] patients, HIV positive patients with a CD4+ cell count <500 cells/mm3, patients on systemic immunosuppressive therapy, and those with haematological malignancy.
kojima je broj CD4+ stanica bio < 500 stanica/mm3, bolesnike liječene sistemskom imunosupresijskom terapijom i bolesnike s hematološkom zloćudnom bolešću.
• One 75 mg Ebilfumin capsule
• jedna Ebilfumin kapsula od 75 mg
During oseltamivir treatment, rare events have been reported that include
Tijekom liječenja oseltamivirom prijavljeni su rijetki događaji koji uključuju: • konvulzije i delirij, uključujući promjenu razine svijesti
18 mg twice daily
18 mg dva puta na dan
A large amount of data on oseltamivir exposure of pregnant women from post-marketing reports and observational studies (more than 1000 exposed outcomes during the first trimester) indicate no malformative nor feto/neonatal toxicity by oseltamivir.
Velika količina podataka o trudnicama izloženima oseltamiviru iz prijava nakon stavljanja lijeka u promet i opservacijskih ispitivanja (više od 1000
12 capsules (540 mg)
12 kapsula (540 mg)
Prevention of influenza: Dose adjustment is recommended for adults and adolescents (13 to 17 years of age) with moderate or severe renal impairment as detailed in the table below.
Prevencija gripe: U odraslih i adolescenata (u dobi od 13 do 17 godina) s umjerenim ili teškim oštećenjem funkcije bubrega preporučuje se prilagodba doze, prema sljedećoj tablici.
Ebilfumin 30 mg hard capsules oseltamivir
Ebilfumin 30 mg tvrde kapsule oseltamivir
Ebilfumin 30 mg, 45 mg and 75 mg capsules are available for infants and children 1 year of age or older
Za dojenčad i djecu u dobi od 1 godine ili stariju na raspolaganju su Ebilfumin 30 mg, 45 mg i 75 mg kapsule.
• One 30 mg Ebilfumin capsule
• jedna Ebilfumin kapsula od 30 mg
9 mg twice daily
9 mg dva puta na dan
Ebilfumin 75 mg hard capsules oseltamivir
Ebilfumin 75 mg tvrde kapsule oseltamivir
However, care should be taken when prescribing oseltamivir in subjects when taking co-excreted agents with a narrow therapeutic margin (e.g. chlorpropamide, methotrexate, phenylbutazone).
Međutim, oseltamivir se mora propisivati s oprezom osobama koje istodobno uzimaju lijekove uske terapijske širine koji se izlučuju na isti način (primjerice klorpropamid,
A total of 1473 children (including otherwise healthy children aged 1-12 years old and asthmatic children aged 6-12 years old) participated in clinical studies of oseltamivir given for the treatment of influenza.
(uključujući inače zdravu djecu u dobi od 1-12 godina i djecu oboljelu od astme u dobi od 6-12 godina).
Oseltamivir reduced the time to alleviation of all symptoms by 0.7 days (95 % CI 0.1 - 1.6 days; p = 0.022) and the duration of fever (≥ 37.8 °C), cough and coryza by one day (95 % CI 0.4 - 1.7 days; p < 0.001) compared to placebo.
(95 % CI 0,1 - 1,6 dana; p = 0,022), a trajanje vrućice (≥37,8%), kašlja i hunjavice za jedan dan
These events are also experienced by patients with influenza without oseltamivir administration.
Takvi događaji su se također javljali kod oboljelih od gripe koji nisu uzimali oseltamivir.
30 mg after each haemodialysis session
30 mg nakon svake hemodijalize bolesnici na peritonejskoj dijalizi*
Detailed information on the home preparation can be found in the package leaflet of Ebilfumin capsules under “Making liquid Ebilfumin at home”.
Podrobne informacije za pripremu kod kuće nalaze se u Uputi o lijeku za Ebilfumin kapsule, u dijelu
1.5 ml twice daily 1.5 ml once daily 2.0 ml (or 3.0 ml)
1,5 ml dvaput dnevno 1,5 ml jednom dnevno 2,0 ml (ili 3,0 ml)
Capsule size: 4
Veličina kapsule: 4
Ebilfumin 45 mg hard capsules
Ebilfumin 45 mg tvrde kapsule
(may affect up to 1 in 10 people)
(mogu se javiti u najviše 1 na 10 osoba)
Yellow iron oxide (E172) Titanium dioxide (E171) Body:
Ovojnica kapsule Kapica: želatina željezov oksid, žuti (E172) titanijev dioksid (E171) Tijelo: želatina titanijev dioksid (E171)
• Conjunctivitis (red eyes and discharge or pain in the eye)
• konjunktivitis (crvene oči te iscjedak ili bol u očima) • upala uha i drugi poremećaji uha
Severe renal impairment
• mučnina Česte nuspojave
15 to 23 kg
15 do 23 kg
75 mg twice daily
75 mg dvaput dnevno
10 capsules (750 mg)
10 kapsula (750 mg)
• Thrombocytopenia (low platelet count)
• trombocitopenija (smanjen broj trombocita)
• One 45 mg Ebilfumin capsule
• jedna Ebilfumin kapsula od 45 mg
Capsule size: 2.
Veličina kapsule: 2.
The median time to resolution of symptoms (TTRS) was similar between the standard dose group (103 hours [90% CI 75.4-110.0]) and double dose group (104 hours [90% CI 65.8-131.0]).
(103 sata [90% CI: 75,4 - 110,0]) i onoj koja je primala dvostruku dozu (104 sata [90% CI:
Package Leaflet: Information for the user Ebilfumin 30 mg hard capsules oseltamivir
Uputa o lijeku: Informacije za korisnika Ebilfumin 30 mg tvrde kapsule oseltamivir
Capsule size: 4.
Veličina kapsule: 4.
6 capsules (450 mg)
6 kapsula (450 mg)
• Cold sore virus
• infekcija virusom herpesa